LONDON, UK (GlobalData), 2 July 2012 - Neurostimulation devices that use electricity to stimulate neurons in the nervous system and are used to treat conditions such as Parkinson’s disease and chronic back pain are becoming more common as the world’s elderly population increases, according to a report by healthcare industry analysts GlobalData.\
The new report* states that the value of the market was $2.3 billion in 2011, but this will almost double by 2018 to reach $4.4 billion in 2018, climbing at a Compound Annual Growth Rate (CAGR) of 10%.
GlobalData largely attributes this growth to expanding patient pools for ailments typically associated with older people: Parkinson’s disease, overactive bladder, chronic pain, essential tremor and dystonia. These conditions cost national healthcare authorities around the world billions of dollars annually, making clinically proven and cost-effective neurostimulation therapy an attractive solution.
Successful treatment outcomes for people with these disorders have led to extensive further research. As a result, the market pipeline consists of traditional applications for neurostimulation therapy, as well as new and innovative ones. In the US, the Food and Drug Administration’s (FDA) fast-track program, intended to facilitate progress and a quick review process, is encouraging companies to invest in the development of advanced neurostimulation devices designed to address serious conditions.
Furthermore, the Centers for Medicare and Medicaid Services (CMS) initiated a New Technology Add-on Payment (NTAP) program that provides payment incentives under Medicare’s inpatient prospective payment system. Beginning in 2001, the program reimburses up to 50% of the cost of the implementation of new technologies, further promoting innovation. Included among the approved technologies under the NTAP program is bilateral Deep Brain Stimulators (DBS) for the treatment of Parkinson’s disease, and rechargeable implantable spinal cord neurostimulators, which are used for the treatment of chronic pain.
According to 2011 figures, Medtronic dominates the global neurostimulation devices market, with a huge 62% share and revenue of $1.4 billion. The firm holds such a strong position due to a number of factors, including 37 manufacturing sites around the world and a presence in the market for over 30 years. St. Jude Medical held the second largest portion with 15% of the market, with Boston Scientific not far behind with a 13% share.
* Neurostimulation Devices – Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 This report provides key data, information and analysis on the global neurostimulation devices market. It also outlines the market landscape and provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
-ABOUT GLOBALDATA-
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@globaldata.com
